Clinical Trial Update: Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions [Phase 4]

View source ↗

Summary

Phase 4 trial update reporting on ustekinumab for anti-TNF–induced psoriasiform skin lesions; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Psoriasis

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Inflammatory Bowel Diseases, Psoriasis | Phase 4 | Status: COMPLETED